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Background Patient-reported outcome measures (PROMs) measure
patients’ perspectives on health outcomes and are increasingly used
in health care. To capture the patient’s perspective, it is essential that
patients are involved in PROM development
Objective This article reviews in what ways and to what extent
patients are involved in PROM development and whether patient
involvement has increased over time.
Search strategy Literature was searched in PubMed, EMBASE,
MEDLINE and the Cochrane Methodology Register.
Inclusion criteria Studies were included if they described a new
PROM development.
Data extraction Basic information and information regarding
patient involvement in development phases was recorded.
Main results A total of 189 studies, describing the development of
193 PROMs, were included. Most PROMs were meant for chronic
disease patients (n = 59) and measured quality of life (n = 28). In
25.9% of the PROM development studies, no patients were
involved. Patients were mostly involved during item development
(58.5%), closely followed by testing for comprehensibility (50.8%),
while patient involvement in determining which outcome to measure
was minimal (10.9%). Some patient involvement took place in the
development of most PROMs, but in only 6.7% patients were
involved in all aspects of the development. Patient involvement did
not increase with time.
Conclusions Although patient involvement in PROM development
is essential to develop valid patient-centred PROMs, patients are not
always involved. When patients are involved, their level of involve-
ment varies considerably. These variations suggest that further
attention to building and/or disseminating consensus on require-
ments for patient involvement in PROM development is necessary.
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Introduction
Patient-reported outcome measures (PROMs)
assess health outcomes from the patients’ per-
spective.1,2 PROMs were originally developed
for the use in clinical research as a way to
measure treatment effectiveness. However,
PROMs are now increasingly used in clinical
practice to monitor and to improve the care
for individual patients and in health policy and
management, for example in the English
National Health Service (NHS), to measure
the performance of health-care providers2,3 or
by the American Centres for Medicare and
Medicaid Services (CMS) to award incentive
payments for eligible professionals.4 Patients
are more and more considered to possess
important experiential knowledge on health
and health care, a source of information that
is relevant for improving quality of care.2–5
To truly capture the patient’s perspective, it is
essential that patients are involved in PROM
development,5–9 as only patients can determine
which health outcomes are relevant for them9–11
and whether the questionnaire captures these
outcomes in a comprehensible and understand-
able manner.12–15 Besides, if a questionnaire fails
to represent the patients’ perspective, it may
result in patients failing to complete the ques-
tionnaire and a negative impact on the
validity.16 Only a few studies investigated patient
involvement in the development of PROMs, and
only for a small number of PROMs, or for a
specific disease.7,17 Nevertheless, there are con-
cerns that there are many PROMs in use where
no patients were involved during the develop-
ment process. Haywood investigated the quality
and acceptability of PROMs used in chronic
fatigue syndrome/myalgic encephalomyelitis and
found no clear evidence of patient involvement
in the development of PROMs.17 Other research
using interviews with patients uncovered concep-
tual difficulties and questionnaire design
problems among a few well-known PROMs
which might have been prevented by involving
patients in the development.7 It appears that
although patient involvement is increasingly
accepted as an essential part of the development
process, we are still using PROMs which were
developed without patient involvement.
Although patient involvement appears to be
neglected in PROM selection and at least in the
development of earlier PROMs, there is some
agreement in the literature on how patients
should be involved. There are several phases in
the development where the input of patients can
be used to create a more patient-centred PROM.
To ensure that the health outcomes and domains
measured with PROMs are relevant for patients,
patients may partake in identifying core out-
comes,10,11 for example by participating in a
reference group or focus groups.18 After estab-
lishing which outcomes should be measured,
patients should be involved in the generation of
items by either focus groups or interviews.12,15,18
While interviews can be used to obtain a number
of personal feelings and opinions on a subject,
which can be especially useful for eliciting the
opinions of minority groups, focus groups may
be useful for obtaining opinions that are likely
to reflect the majority.1,19 Choosing between
these methods may also be dependent upon the
patient population or practical considerations.20
Item development may have some overlap with
the phase where core outcomes are identified,
because although they have different purposes,
both could take place using the same qualitative
methods. After item development, it is impor-
tant to determine that the questionnaire is
comprehensible and that the content is valid for
patients.12–15 Structured cognitive interviews are
an established way to ensure this12,13 by enabling
researchers to determine how items are inter-
preted by potential respondents and how a
response is formed.13,15
It appears that there are at least three phases
in which patients can be involved in the develop-
ment of PROMs, determining important health
outcomes, item generation and checking for
comprehensibility and content validity. How-
ever, as mentioned before, PROM development
procedures are not standardized regarding
patient involvement and the few studies who
looked at patient involvement in the develop-
ment of PROMs reported variations in whether
and to what extent patients are involved in the
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development.7,17 As patient involvement is such
an important factor in the development of
PROMs,5,9–15,21 it is of the utmost importance
that all the parties involved are aware of the level
of patient involvement of a PROM if it comes to
selecting a PROM or interpreting PROM
results. Additionally, awareness of the current
situation regarding patient involvement is neces-
sary so that all parties can act accordingly to
ensure the development and use of valid patient-
centred PROMs. Therefore, by conducting a
scoping review, this study aims to review the
level of patient involvement in PROMs develop-
ment. We expect to find more patient
involvement in recently developed PROMs as
compared to older PROMs, as the importance
of the patients’ perspective is increasingly
stressed.2–5 In summary, our research questions
are as follows:
1. In what ways and to what extent have
patients been involved in the development of
PROMs?
2. Has patient involvement in the development
of PROMs increased with time?
Methods
Scoping review
This study is a scoping review. Scoping reviews
are used to give a unique overview, in this case
of patient involvement in the development of
PROMs. For a scoping review, studies are not
excluded based on type of study (as long as a
description of a PROM development was
included), type of participants, type of health
care or development techniques. Furthermore,
studies are not assessed on aspects of method-
ological quality. Characteristics of a scoping
review can be a lack of a narrow review ques-
tions, the inclusion of studies which have
employed a range of data collection and analysis
techniques, the quality of the included studies is
not assessed and the subject has not been sub-
jected to a review before.22 Although we did not
conduct a systematic review, the PRISMA state-
ment23 was followed where possible.
Search strategy
The search was conducted on 15 May 2014 by
author BW. The databases used were PubMed,
the Cochrane Methodology register, MEDLINE
and EMBASE. The search terms were the mesh
terms: (‘Outcome Assessment (Health Care)/
methods ‘[Mesh] OR proms[tiab] OR ‘patient
reported outcome measures ‘[tiab]) AND (ques-
tionnaires[mesh] OR questionnaire*[tiab]).a The
terms were determined after an initial search of
the literature and advice from a librarian with
expertise in health services research and system-
atic reviews. Studies describing translations or
alterations of PROMs were checked for refer-
ences to original PROM development studies.




Studies were included if they described the devel-
opment of a new PROM. A PROM is a
questionnaire which measures patients’ perspec-
tives on health outcomes.1,2 We considered the
development of a PROM the process from
establishing which outcomes to measure until
the psychometric testing. This includes deter-
mining which outcome to measure, item
development and testing the questionnaire on
comprehensibility. Studies were included if they
described (a part of) these phases.
Exclusion criteria
Studies which describe the development of a
short version, alteration or translation of one
already existing questionnaire do not usually go
through all the development phases and were
therefore excluded. Short versions and adapta-
tions were considered closely to ensure that only
studies were excluded which adapted an existing
aThese search terms are related to the PubMed search. Simi-
lar versions were used to search the Cochrane Methodology
register, MEDLINE and EMBASE but adapted for the
search terms used in these databases.
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PROM very slightly or shortened a PROM with-
out making any fundamental changes.
Post hoc exclusion criteria
Studies were excluded if they did not concern a
published manuscript or if the manuscript was
written in a language other than English, Ger-
man, Dutch or French. As only two manuscripts
were written in a different language, the impact
was limited.
Study eligibility
Author DB independently scored ten per cent
of the abstracts on eligibility, after which dis-
agreements were discussed. The inter-rater
agreement on study eligibility, calculated using
the kappa statistic, was 0.71 (95% CI: [0.50,
0.92]). Full-text selection by a second reviewer
was deemed unnecessary as the reasons for
exclusion were mostly very clear. However,
authors DD and DB independently assessed the
eligibility of 10 full texts. Additionally, full
texts which were excluded because the question-
naire that was developed measured the process
of care instead of outcomes, were discussed
among the authors. There were no disagree-
ments. See Fig. 1 for details on the literature
selection process.
Data extraction
The basic information that was collected from
each article included the first author, the year of
publication, the country, the health problem or
treatment associated with the PROM, whether
the patient group concerned adults, parents
or children, whether the PROM is generic or





Abstract assessed by BW 
(100%) and DB (10%). 
(n = 4160)
Remaining abstracts (n = 
144)
Full texts assessed by BW 
(n = 219)
10 full texts assessed by 
DB and DD for eligibility
n = 189
329 duplicates excluded
4016 studies excluded  
the criteria
30 studies excluded 
the criteria
75 studies included from 




Figure 1 Search flow.
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specific, the health outcome measured, and the
care type associated with the health problem.
To gain insight into patient involvement in the
development of PROMs, additional information
was recorded which is displayed in Table 1.
Authors DD and DB extracted the data for
10 studies. Disagreements were discussed, after
which the categories were further specified. Main
discussion points were as follows:
1. Generic or specific? Initially, we defined a
PROM as generic if everyone in the general
population could answer the questions and a
PROM as specific if it covered a specific dis-
ease. However, several PROMs were not
generic, but covered health problems relevant
for more than one disease, such as pain or
fatigue. Conventional definitions24 would
label this category as specific as it measures a
specific concept. However, most of these
questionnaires can be used for a far larger
group of patients than a disease-specific
questionnaire could, which is why we gave
this group of questionnaires the label
‘semi-generic’.
2. What is regarded as patient involvement in
determining which health outcome to mea-
sure? Although ideally patients are involved
from the start of the development by asking
them what outcomes are important to them,
this is extremely rare. Therefore, we broad-
ened this category to include cases where
patients contributed to the development of
the framework or domains within an estab-
lished outcome or where patient suggestions
were not restricted in any way.
Statistics
A chi-square test using the variables ‘Health out-
come measured as outcome of surgery, cancer,
chronic disease, mental health, other, lifelong
disorder’ and ‘patient involvement (‘yes’ or
‘no’)’ was conducted to give insight into whether
the level of patient involvement is influenced by
the patient population for which the PROM is
meant. To analyse patient involvement in
PROM development over time, we distinguished
between three time periods: before 2005, 2006–
2010 and after 2010. The choice of these time
frames was quite arbitrary, but it resulted in
three groups of more or less equal size. The
dependent variable described whether any
patient involvement had taken place (‘yes’ or
‘no’). A chi-square test was conducted to analyse
whether patient involvement differs between
these three time periods. Post hoc pair wise com-
parisons were conducted using a chi-square test.
Additional analyses were performed using differ-
ent time periods: before and after 2006 (mean of
PROM publication dates), before and after 2008
(median of PROM publication dates) and time




As shown in Fig. 1, 4489 studies were identified
from the databases PubMed, EMBASE, MED-
LINE and the Cochrane methodology register.
After a search for duplicates, 329 were removed,
leaving 4160 studies. Of these studies, 219 stud-
ies remained after selecting abstracts which
appeared to meet the inclusion criteria. Finally,
a full-text selection resulted in 189 studies. The
studies excluded during full-text selection were
mostly presentations (n = 10), adaptations of
already existing PROMs (n = 9) or patient-
reported experience measures (n = 4).
Study characteristics
The 189 studies were published from 1980 until
2014 and described the development of 193
PROMs. The PROMs were mostly developed in
the USA (n = 69), the UK (n = 62) and Ger-
many (n = 17). Most PROMs were developed
for a specific patient group (n = 152) or few
patient groups (n = 32). Nine questionnaires
were generic. Of the 193 PROMs, 180 question-
naires were meant to be filled out by adults and
one by parents. A range of patient populations
were included, from haemophilia (n = 6) and
ª 2016 The Authors. Health Expectations Published by John Wiley & Sons Ltd
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mental health patients (n = 5) to diabetes
patients (n = 4). The majority of the PROMs
were meant for chronic disease patients (n = 59)
or for patients undergoing surgery (n = 25).
Most PROMs measured solely quality of life
(n = 28), health-related quality of life (n = 21) or
health status (n = 15). Both relatively unknown
PROMs and much used PROMs such as the SF-
36, the EQ-5D and the KOOS were included in
the review.
Patient involvement
In the development of 74.1% of PROM patients
were involved in some way, leaving 25.9 per cent
of PROMs without any patient involvement
(Table 2). Patients were mostly involved in the
item development (58.5%), especially using
interviews (31.6%). Testing for comprehensibil-
ity closely followed item development (50.8%),
while patients were never involved in determin-
ing which outcome should be measured.
However, in some cases, patients were not lim-
ited to just the predetermined outcome and all
suggestions were included (1.0%), and in some
cases, patients were involved in developing the
domains or a framework (9.8%). These exam-
ples of patient involvement together suggest
some limited patient involvement in determining
which outcome to measure in some PROMs
(10.9%). In 6.7% of the PROM development
studies, patients were involved in all the develop-
ment phases we documented. The level of
patient involvement did not differ dependent on
whether the PROM was developed as a measure-
ment of a health outcome of surgery, cancer,
chronic disease, mental health or a lifelong dis-
order (v2 (6) = 7.063, P = 0.315). There is a
small significant difference between the levels of
patient involvement for the three time periods
(v2 (2) = 6.511, P = 0.039). Patient involvement
was significantly lower between the years 2006
and 2010 compared to after 2010 (v2 (1) = 6.545,
P = 0.011), but no significant difference was
found between before 2005 and after 2010 (v2
(1) = 2.872, P = 0.090) and between before 2005
and 2006–2010 (v2 (1) = 1.048, P = 0.306). Sen-
sitivity analyses using different time periods
showed similar results.
Discussion
As patient involvement in the development of
PROMs is essential for measuring patient rele-
vant outcomes,5–9 this study aimed to review
whether and to what extent patients have been
involved in the development of PROMs. In most
PROM development studies, some patient
involvement is recorded, but only in a few cases,
patients have been involved throughout the
development process. Surprisingly, in more than
a quarter of PROM development studies, patient
involvement was not documented at all. Other
research looking at patient involvement in the
development of PROMs for certain health prob-
lems suggests similar or even less favourable
results for patient involvement.7,17
Besides patient involvement in development
phases, this review also investigated whether
patient involvement increased with time. We
Table 2 Patient involvement in the development of patient-
reported outcome measures (PROMs) (n = 193)
n %
Patient involvement in
any phase of the development*
143 74.1
Patient involvement in one phase 67 34.7
Patient involvement in two phases 63 32.6
Patient involvement in three phases 13 6.7
Establishing which outcome to measure 21 10.9
Unrestricted input from patients 2 1.0
Patient involvement in the
development of frameworks or domains
19 9.8
Item development 113 58.5
Focus groups with patients 42 21.8
Interviews with patients 61 31.6




Cognitive interviews 48 24.9
Other methods involving patients 55 28.5
Patient involvement before 2005 53 73.6
Patient involvement between 2006 and 2010 46 65.7
Patient involvement after 2010 44 86.3
*Questionnaire development was divided into three development
phases: establishing which outcome to measure, item development
and testing for comprehensibility.
ª 2016 The Authors. Health Expectations Published by John Wiley & Sons Ltd
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expected that, as the patients’ perspective is
increasingly regarded as important,2–5 patients
would be more involved in recently developed
PROMs. There appeared to be some differences
in patient involvement, but none that suggest an
increase of patient involvement over time. This
is especially surprising because patient involve-
ment is not only recommended by many
researchers,5–9 a few years ago it has also
become a requirement if the PROM is used in
medical product development.26 However, in
ISOQOL’s reporting standards for the use of
PROMs in randomized controlled trials,27 the
issue of patient involvement was rejected after
consideration. Similarly, the COSMIN checklist,
which assesses the methodological quality of
studies on measurement properties of PROMs,21
barely mentions patient involvement. It only
asks to check whether the items are relevant to
the study population and whether the question-
naire was pre-tested, for example using cognitive
interviews. Apparently, patient involvement is
still not always considered important enough to
be included in reporting formats. Additionally,
although many benefits may be gained by
involving patients during the development pro-
cess, patient involvement can also result in
budget and time issues,9,28 which may prevent
PROM developers from involving patients. Dif-
ferences in requirements regarding patient
involvement and negative consequences of
patient involvement may explain the variation
we found in the level of patient involvement and
the lack of a significant increase in patient
involvement over time.
If patients are still not always involved, and if
the involvement varies in intensity (from letting
some patients comment on the questionnaire in
writing after completing it, to the whole process
of organizing focus groups, interviews and cog-
nitive interviews), what does this mean for the
validity of the questionnaires and for the use of
their results by patients, health professionals
and health insurers? Patient involvement is seen
as essential to ensure the content validity of the
questionnaire.12–15 Involving patients by focus
groups or interviews during item development
ensures a better understanding of illness experi-
ence20 and could help challenge tacit models on
which PROM designs are based.29 Furthermore,
the content of the questionnaire may be less rele-
vant to patients if they are not involved in the
development. This, in turn, may lead to a nega-
tive attitude towards the questionnaire and
failure to answer the questions. All this can neg-
atively affect the validity of a survey.16 Based on
the findings of this review, it appears that the
content validity of many PROMs can be
improved. This is troubling as PROMs are
increasingly used to inform patients, to improve
the care of individual patients and to assist pur-
chasers.2,3,30,31 PROMs may be used to improve
the care of individual patients by increasing
health professionals’ awareness of, and ability
to, address patients’ concern.32 However, to use
PROMs for this purpose, it is essential that a
PROM is used which reflects the patients’ needs
and concerns accurately.33 Furthermore, patient
information based on PROMs may not suffi-
ciently cover aspects that are most relevant
to patients.
In the Netherlands, as well as in the English
NHS and the American Medicare and Medi-
caid system, the use of PROMs in models of
payment by results is a particularly relevant
issue. In the Netherlands in 2006, managed
competition has been introduced. In this sys-
tem, health insurers should contract providers
based on quality and costs of care. To do so,
health insurers need instruments for measuring
the quality of the care delivered by providers.34
Besides measures of effectiveness and safety
and patient experience measures,35 PROMs are
slowly introduced in the Netherlands to assist
health insurers in selecting the best providers
for contracting. In theory, this is a good thing,
as PROMs are meant to reflect the patient’s
perspective1 and research suggests that patients
have a different view on which aspects of their
care are important to them. Identifying and
understanding which aspects of care are the
most important to patients may be the key to
good care.36 However, if the validity of
PROMs may need to be improved and if
PROMs do not always reflect the patient’s per-
spective, health insurers may want to ask
ª 2016 The Authors. Health Expectations Published by John Wiley & Sons Ltd
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themselves whether they are going to select
health providers for the right reasons.
Limitations
The present findings should be regarded with
some caution because of study limitations.
First, patient involvement was recorded using
the documentation of the development process
in the included articles. The results are there-
fore dependent on the quality and accuracy of
the documentation. Patient involvement may
go unnoticed if it is not documented in the
article describing the development. Second,
reporting standards may have improved over
time and although patient involvement was
recorded almost as many times in older publi-
cations as in recent publications, a lower
standard of reporting may mean that levels of
patient involvement in earlier studies have been
underestimated. Third, not all development
studies were documented in detail and some-
times PROM developers used one method for
several development phases, which occasionally
made it difficult to separate the development
phases. However, to ensure that patient
involvement was not underestimated, we
recorded any suggestion that a method was
used for more than one phase as patient
involvement during several development
phases. Fourth, as we wanted to compare
PROMs on patient involvement during the
three phases of development, we selected stud-
ies describing one or more of these phases.
However, sometimes PROMs are further devel-
oped after the conclusion of these phases. As
further development is very difficult to identify
and the methods used for further development
can vary greatly, we were unable to include
this. Nevertheless, it is possible that for some
of the PROMs included in this review, a higher
level of patient involvement has been practised
following the initial development. Fifth,
although we were able to compare the PROMs
on patient involvement in three development
phases, we could not compare the PROMs on
the level of patient involvement during these
phases. The amount of information that is
given in publications varies hugely and often
lacks detailed information on patient involve-
ment. Sixth, statistical analyses were performed
on data which was not derived from a system-
atic review. Although systematic review
guidelines were followed where possible, the
included papers may not be a complete reflec-
tion of all PROM development papers, which
may have implications for the interpretation of
the results.
Implications
This review may have several implications for
the use and development of PROMs. First, a
consensus should be reached on how patients
should be involved in the development of
PROMs. In this review several studies, describ-
ing opportunities to involve patients were
brought together to use as a guide for extracting
data concerning patient involvement from the
papers. However, to ensure that all PROMs
incorporate patient involvement throughout
their development phases, it is important that
one, easy to use, guideline is created. Perhaps
inspiration may be gained from best practice
examples such as the Genetic Counseling Out-
come Scale37 and the Breast-Q,38 where patients
were involved throughout the development pro-
cess. In the development of an instrument for
fatigue in rheumatoid arthritis, patients were
even given the role of research partners.39 Prefer-
ably the guideline is developed involving
researchers, professionals, relevant organiza-
tions and patients to ensure input from all
stakeholders and a widespread acceptation of
the guideline.
Besides a guideline for patient involvement in
PROM development, the implementation of a
guideline for how to report the methods used to
involve patients in publications is also necessary.
As patient involvement is necessary to ensure
that the questionnaire measures the patients’
perspective,5–9 existing PROMs should be
selected based on the level of patient involve-
ment. However, certain information about the
development process is necessary for comparing
PROMs on patient involvement. Although an
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attempt at guiding researchers in reporting
patient involvement has been made,40 studies
still offer varying amounts of information about
their development process. This makes it very
difficult to select a PROM based on its level of
patient involvement. A guideline that is sup-
ported by all relevant parties and enforced by
journals should help ensure that all publications
include information needed to make an
informed choice for a PROM.
Third, besides patient involvement in the
development of PROMs, patients may also be
involved in the interpretation and presentation
of PROM results. Patients may be involved in
the interpretation of PROM results using impor-
tance ratings. Importance ratings may give an
indication of patient’s values, needs and expecta-
tions regarding health care.41 Importance
ratings enable the weighting of the PROM
results according to the importance patients
allocate towards aspects of the PROM. Further-
more, as patients can use PROM data to make
an informed decision concerning health-care
providers or treatments,30,31 PROM results
should be freely available and easy to read.
Patient involvement in the presentation of the
results could help easy use of PROMs
by patients.
Conclusion
Although some patient involvement takes place
in most PROM development studies, the level of
patient involvement varies greatly. Furthermore,
in more than a quarter of PROM development
studies, no patient involvement was recorded.
This lack of patient involvement throughout the
development may have consequences for how
well the questionnaire reflects the patient’s per-
spective, which in turn may result in limited
benefits for the use of PROMs in individual care,
for making decisions by patients between treat-
ments and health professionals and, finally, for
rewarding health professionals or even selec-
tively buying health care from certain health
professionals. For PROMs to truly measure
the patient’s perspective, further attention to
building and/or disseminating consensus on
requirements for patient involvement in the
development of PROMs is necessary and exist-
ing PROMs should be carefully selected on the
level of patient involvement.
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